Angiotensin-(1-7) prevents angiotensin ii-induced fibrosis in cremaster microvessels

Microcirculation

Volumn 22, Issue 1, 2015, Pages 19-27

  Carver, Kyle A ^a   Smith, Thomas L ^a   Gallagher, Patricia E ^a   Tallant, E Ann ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Angiotensin (1 7); Connective tissue growth factor; DUSP1; Fibrosis; MAP kinase; Microvasculature; Microvessels; Remodeling; Smad

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN[1-7]; CONNECTIVE TISSUE GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; ANGIOTENSIN I; ANGIOTENSIN I (1-7); ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; CTGF PROTEIN, RAT; DUSP1 PROTEIN, RAT; MADH2 PROTEIN, RAT; MADH3 PROTEIN, RAT; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PEPTIDE FRAGMENT; SMAD2 PROTEIN; SMAD3 PROTEIN; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; CONTROLLED STUDY; CREMASTER MUSCLE; FIBROSING ALVEOLITIS; HEART RATE; HYPERTENSION; MALE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SYSTOLIC BLOOD PRESSURE; UPREGULATION; VASCULAR FIBROSIS; ANIMAL; BLOOD PRESSURE; CHRONIC DISEASE; DRUG EFFECTS; FIBROSIS; LEWIS RAT; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; VASCULARIZATION;

RATTUS;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIOLES; BLOOD PRESSURE; CHRONIC DISEASE; CONNECTIVE TISSUE GROWTH FACTOR; DUAL SPECIFICITY PHOSPHATASE 1; FIBROSIS; HYPERTENSION; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SKELETAL; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RATS; RATS, INBRED LEW; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VASOCONSTRICTOR AGENTS;

EID: 84922625689     PISSN: 10739688     EISSN: 15498719     Source Type: Journal    
DOI: 10.1111/micc.12159     Document Type: Article

References (53)

1. Acuna MJ, Pessina P, Olguin H, Cabrera D, Vio CP, Bader M, Munoz-Canoves P, Santos RA, Cabello-Verrugio C, Brandan E. Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-beta signalling. Hum Mol Genet 23: 1237-1249, 2013.
2. Benter IF, Yousif MH, Anim JT, Cojocel C, Diz DI. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol 290: H684-H691, 2006.
3. Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol 21: 473-482, 2002.
4. Buus NH, Mathiassen ON, Fenger-Gron M, Praestholm MN, Sihm I, Thybo NK, Schroeder AP, Thygesen K, Aalkjaer C, Pedersen OL, Mulvany MJ, Christensen KL. Small artery structure during antihypertensive therapy is an independent predictor of cardiovascular events in essential hypertension. J Hypertens 31: 791-797, 2013.
5. Chen Y, Blom IE, Sa S, Goldschmeding R, Abraham DJ, Leask A. CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int 62: 1149-1159, 2002.
6. Christensen KL, Mulvany MJ. Mesenteric arcade arteries contribute substantially to vascular resistance in conscious rats. J Vasc Res 30: 73-79, 1993.
7. Cook KL, Metheny-Barlow LJ, Tallant EA, Gallagher PE. Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors. Cancer Res 70: 8319-8328, 2010.
8. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension 30: 535-541, 1997.
9. Folkow B. Hypertensive structural changes in systemic precapillary resistance vessels: how important are they for in vivo haemodynamics? J Hypertens 13: 1546-1559, 1995.
10. Gao X, He X, Luo B, Peng L, Lin J, Zuo Z. Angiotensin II increases collagen I expression via transforming growth factor-beta1 and extracellular signal-regulated kinase in cardiac fibroblasts. Eur J Pharmacol 606: 115-120, 2009.
11. Giani JF, Burghi V, Veiras LC, Tomat A, Munoz MC, Cao G, Turyn D, Toblli JE, Dominici FP. Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. Am J Physiol Renal Physiol 302: F1606-F1615, 2012.
12. Gomez-Garre D, Martin-Ventura JL, Granados R, Sancho T, Torres R, Ruano M, Garcia-Puig J, Egido J. Losartan improves resistance artery lesions and prevents CTGF and TGF-beta production in mild hypertensive patients. Kidney Int 69: 1237-1244, 2006.
13. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK, Katovich MJ. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 292: H736-H742, 2007.
14. Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 290: H2417-H2423, 2006.
15. Hashimoto H, Prewitt RL, Efaw CW. Alterations in the microvasculature of one-kidney, one-clip hypertensive rats. Am J Physiol 253: H933-H940, 1987.
16. Huang ML, Li X, Meng Y, Xiao B, Ma Q, Ying SS, Wu PS, Zhang ZS. Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors. Clin Exp Pharmacol Physiol 37: e1-e6, 2010.
17. Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, Ferrario CM, Raizada MK. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 90: 783-790, 2005.
18. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 38: 581-587, 2001.
19. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, Greenberg BH. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 289: H2356-H2363, 2005.
20. James MA, Tullett J, Hemsley AG, Shore AC. Effects of aging and hypertension on the microcirculation. Hypertension 47: 968-974, 2006.
21. Javelaud D, Mauviel A. Mammalian transforming growth factor-betas: Smad signaling and physio-pathological roles. Int J Biochem Cell Biol 36: 1161-1165, 2004.
22. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Ishimura Y, Chatani F, Iwao H. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther 273: 509-515, 1995.
23. Leask A, Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol 81: 355-363, 2003.
24. Lubel JS, Herath CB, Tchongue J, Grace J, Jia Z, Spencer K, Casley D, Crowley P, Sievert W, Burrell LM, Angus PW. Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. Clin Sci (Lond) 117: 375-386, 2009.
25. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 19: 2783-2810, 2005.
26. Mathiassen ON, Buus NH, Sihm I, Thybo NK, Morn B, Schroeder AP, Thygesen K, Aalkjaer C, Pedersen OL, Mulvany MJ, Christensen KL. Small artery structure is an independent predictor of cardiovascular events in essential hypertension. J Hypertens 25: 1021-1026, 2007.
27. McCollum LT, Gallagher PE, Tallant EA. Angiotensin-(1-7) attenuates angiotensin II-induced cardiac remodeling associated with up-regulation of dual specificity phosphatase 1. Am J Physiol Heart Circ Physiol 302: H801-H810, 2011.
28. McCollum LT, Gallagher PE, Tallant EA. Angiotensin-(1-7) abrogates mitogen-stimulated proliferation of cardiac fibroblasts. Peptides 34: 380-388, 2012.
29. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 38: 635-638, 2001.
30. Ohta K, Kim S, Hamaguchi A, Yukimura T, Miura K, Takaori K, Iwao H. Role of angiotensin II in extracellular matrix and transforming growth factor-beta 1 expression in hypertensive rats. Eur J Pharmacol 269: 115-119, 1994.
31. Ono Z, Prewitt RL, Stacy DL. Arteriolar changes in developing and chronic stages of two-kidney, one clip hypertension. Hypertension 14: 36-43, 1989.
32. Park JB, Intengan HD, Schiffrin EL. Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension. J Renin Angiotensin Aldosterone Syst 1: 40-45, 2000.
33. Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 19: 921-930, 2001.
34. Passos-Silva DG, Verano-Braga T, Santos RA. Angiotensin-(1-7): beyond the cardio-renal actions. Clin Sci (Lond) 124: 443-456, 2013.
35. Peiro C, Vallejo S, Gembardt F, Palacios E, Novella S, Azcutia V, Rodriguez-Manas L, Hermenegildo C, Sanchez-Ferrer CF, Walther T. Complete blockade of the vasorelaxant effects of angiotensin-(1-7) and bradykinin in murine microvessels by antagonists of the receptor Mas. J Physiol 591: 2275-2285, 2013.
36. Raffai G, Durand MJ, Lombard JH. Acute and chronic angiotensin-(1-7) restores vasodilation and reduces oxidative stress in mesenteric arteries of salt-fed rats. Am J Physiol Heart Circ Physiol 301: H1341-H1352, 2011.
37. Rizzoni D, Porteri E, Boari GE, De CC, Sleiman I, Muiesan ML, Castellano M, Miclini M, Agabiti-Rosei E. Prognostic significance of small-artery structure in hypertension. Circulation 108: 2230-2235, 2003.
38. Rizzoni D, Porteri E, De CC, Sleiman I, Rodella L, Rezzani R, Pairdi S, Bianchi R, Ruggeri G, Goari GE, Muiesan ML, Salvett M, Zani F, Miclini M, Rosei EA. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension 45: 659-665, 2005.
39. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 111: 2509-2517, 2005.
40. Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ, Egido J. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension 38: 1382-1387, 2001.
41. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 74: 196-206, 2007.
42. Ruiz-Ortega M, Ruperez M, Esteban V, Egido J. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 5: 73-79, 2003.
43. Ruperez M, Lorenzo O, Blanco-Colio LM, Esteban V, Egido J, Ruiz-Ortega M. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 108: 1499-1505, 2003.
44. Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol 216: R1-R17, 2013.
45. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100: 8258-63, 2003.
46. Schiffrin EL. Reactivity of small blood vessels in hypertension: relation with structural changes. State of the art lecture. Hypertension 19: II1-II9, 1992.
47. Shimizu M, Tanaka R, Uchida M, Orito K, Shimamura S, Yamane Y. Effect of Angiotensin II Type 1 receptor blocker on cardiac angiotensin-converting enzyme and chymase-like activities, and cardiac fibrosis in cardiomyopathic hamsters. J Vet Med Sci 68: 227-233, 2006.
48. Simoes E, Silva AC, Silveira KD, Ferreira AJ, Teixeira MM. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 169: 477-492, 2013.
49. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 289: H1560-H1566, 2005.
50. Tharaux PL, Chatziantoniou C, Fakhouri F, Dussaule JC. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension 36: 330-336, 2000.
51. Wang W, Huang XR, Canlas E, Oka K, Truong LD, Deng C, Bhowmick NA, Ju W, Bottinger EP, Lan HY. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 98: 1032-1039, 2006.
52. Yang F, Chung AC, Huang XR, Lan HY. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension 54: 877-884, 2009.
53. Zeng W, Chen W, Leng X, He JG, Ma H. Chronic angiotensin-(1-7) administration improves vascular remodeling after angioplasty through the regulation of the TGF-beta/Smad signaling pathway in rabbits. Biochem Biophys Res Commun 389: 138-144, 2009.